Article
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2017
Shi Y K, Wang L, Han B H, Li W, Yu P, Liu Y P, Ding C M, Song X, Ma Z Y, Ren X L, Feng J F, Zhang H L, Chen G Y, Han X H, Wu N, Yao C, Song Y, Zhang S C, Song W, Liu X Q, Zhao S J, Lin Y C, Ye X Q, Li K, Shu Y Q, Ding L M, Tan F L, Sun Y
Abstract excerpt
BACKGROUND: Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.